Inflammation Accelerates BCR-ABL1+ B-ALL Development Through Upregulation of AID
Overview
Authors
Affiliations
Inflammation contributes to the initiation and disease progression of several lymphoid malignancies. BCR-ABL1-positive B-cell acute lymphoblastic leukemia (BCR-ABL1+ B-ALL) is triggered by the malignant cloning of immature B cells promoted by the BCR-ABL1 fusion gene. However, it is unclear whether the mechanism driving the disease progression of BCR-ABL1+ B-ALL involves inflammatory stimulation. Here, we evaluate BCR-ABL1+ B-ALL cells' response to inflammatory stimuli lipopolysaccharide (LPS) in vitro and in vivo. The results indicate that LPS promotes cell growth and genomic instability in cultured BCR-ABL1+ B-ALL cells and accelerates the BCR-ABL1+ B-ALL development in a mouse model. We show that the LPS-induced upregulation of activation-induced deaminase (AID) is required for the cell growth and disease progression of BCR-ABL1+ B-ALL. Moreover, AID modulates the expression of various genes that are dominated by suppressing apoptosis genes and upregulating DNA damage-repair genes. These genes lead to facilitation for BCR-ABL1+ B-ALL progression. The heat shock protein 90 (Hsp90) inhibitors significantly reduce AID protein level and delay the disease progression of BCR-ABL1+ B-ALL upon inflammatory stimulation. The present data demonstrate the causative role of AID in the development and progression of BCR-ABL1+ B-ALL during inflammation, thus highlighting potential therapeutic targets.
Kitamura A, Yanagi S, Shide K, Sato Y, Kamiunten A, Yamanari Y Am J Case Rep. 2024; 25:e945804.
PMID: 39736074 PMC: 11694771. DOI: 10.12659/AJCR.945804.
Inflammation as a driver of hematological malignancies.
Saluja S, Bansal I, Bhardwaj R, Beg M, Palanichamy J Front Oncol. 2024; 14:1347402.
PMID: 38571491 PMC: 10987768. DOI: 10.3389/fonc.2024.1347402.
Vogt M, Dienstbier N, Schliehe-Diecks J, Scharov K, Tu J, Gebing P Cell Death Dis. 2023; 14(12):799.
PMID: 38057328 PMC: 10700369. DOI: 10.1038/s41419-023-06337-3.
Libura M, Karabin K, Tyrna P, Czyz A, Makuch-Lasica H, Jazwiec B Cancers (Basel). 2023; 15(22).
PMID: 38001691 PMC: 10670434. DOI: 10.3390/cancers15225431.